Register

Home Fangda represented Shanghai MicroPort Investment Holding Co., Ltd. in its equity acquisition and capital subscription of Suzhou Argus Medical Technology Co., Ltd. at a total consideration of RMB372.3 million

The press releases published in this section have been uploaded by law firms. Their content has not been appraised or edited by Law.asia, and no responsibility is taken for the accuracy of the information they contain or any misrepresentation therein. For our independent editorial content, please visit our homepage.

Fangda represented Shanghai MicroPort Investment Holding Co., Ltd. in its equity acquisition and capital subscription of Suzhou Argus Medical Technology Co., Ltd. at a total consideration of RMB372.3 million

: Description

Fangda represented Shanghai MicroPort Investment Holding Co., Ltd. (“MicroPort Investment”) in its equity acquisition and capital subscription of Suzhou Argus Medical Technology Co., Ltd. (“Argus”) at a total consideration of RMB372.3 million. The transaction was announced in October 2021. Following the consummation of the transaction, MicroPort Investment will hold 51% equity interests in Argus. Subject to the satisfaction of certain milestones, MicroPort Investment has the right the further increase its investment in Argus. This transaction was led by Fangda partners Miles Ma, Diana Li and Sherry Xu, and the team members include Chen Lu, Tingting Huang, Xiaobo Wen and Rui Miao.

MicroPort Investment is a wholly owned subsidiary of MicroPort Scientific Corporation (00853.HK), a HKEX listed medical devices company with its business in multiple fields, including orthopedics, cardiovascular intervention, cardiac rhythm management, electro-physiology, endovascular and peripheral vascular intervention.

Argus is a medical devices company primarily engaged in the business of design, development and sale of intravascular Optical Coherence Tomography (OCT) system solutions.